Michael Ringel is Boston Consulting Group's global leader for innovation analytics and research and product development, and is a core member of the firm’s Corporate Finance & Strategy practice. 

Since joining the firm in 1999, Michael has worked with biotech and pharmaceutical clients on topics such as disease area strategy, transformation and process optimization, sourcing and partnerships, and organization design. He also has extensive experience in mergers and acquisitions, licensing strategy, valuation, and post-merger integration. 

Michael is a frequent contributor to industry journals, including Nature Reviews Drug Discovery, and has coauthored numerous BCG reports on innovation, R&D, and corporate strategy. He sits on the board of The Nature Conservancy in Massachusetts. 

Before joining BCG, Michael worked in academia, investigating theoretical population dynamics and conducting field research in the Amazon basin near Manaus, Brazil.


  • PhD, biology, Imperial College, University of London; National Science Foundation and Fulbright fellowships
  • JD, cum laude, Harvard Law School
  • BA, biology, summa cum laude, ranked number one in the department, Princeton University